New medication for stable schizophrenia
Part of Mental health clinical trials.
This trial tests a new medication (HHK101) for people with stable schizophrenia. It aims to see if the drug is safe and how it works in the body. Participants must be on a steady dose of their current antipsychotic.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old, weigh at least 45 kg (about 99 lbs), and have a body mass index (BMI) between 19 and 35.
- You have been diagnosed with stable schizophrenia and have been taking the same antipsychotic medication at the same dose for at least 4 weeks before the trial starts.
- Your schizophrenia symptoms are not too severe, as measured by a standard psychiatric scale.
- You do not have any serious heart, brain, or movement disorders, such as heart failure, stroke, Parkinson's disease, or tardive dyskinesia.
- You are not allergic to 3 or more different substances and do not have active allergies.
- You are not pregnant, not planning to become pregnant, and will use effective birth control during the trial and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
This study tests a new medicine, KR23248, in healthy people to see if it is safe and how the body handles it. It is a first-in-human trial, so the main goal is to find out about side effects and how the drug moves through the body.
This trial tests a new medication called SEP-363856 over a long period for people with schizophrenia who are currently stable. It looks at how well the drug works and its safety over time.
This study is testing how safe and tolerable an investigational medication is over the long term (52 weeks) when added to your current antipsychotic treatment. It's for people with schizophrenia whose symptoms are stable, and it aims to see if the new medication can help without causing serious side effects.
This study tests an experimental medication (NBI-1117570) for adults with schizophrenia who are currently in the hospital because of a sudden worsening of symptoms. The goal is to see if this new treatment can help control symptoms better.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.